SCHEDULE: Paradigm BioCapital Reports Stake in Edgewise Therapeutics

Paradigm BioCapital Advisors LP and its affiliates have reported beneficial ownership of 9.5% of Edgewise Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Paradigm BioCapital Advisors LP, along with Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., have filed a Schedule 13G.
• This filing indicates a change in beneficial ownership of Edgewise Therapeutics, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially own 10,215,455 shares, representing 9.5% of the outstanding common stock.
• The Paradigm BioCapital International Fund Ltd. directly beneficially owns 8,961,631 shares, which is 8.3% of the outstanding common stock.
• The filing states that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial disclosures.

Positives

• Significant investment by Paradigm BioCapital indicates confidence in Edgewise Therapeutics' long-term prospects.
• The reporting persons hold sole voting and dispositive power over their beneficially owned shares, suggesting clear investment strategy.

Negatives

• The filing does not provide any new operational or financial performance data for Edgewise Therapeutics.
• The large stake could potentially lead to future activism or influence on company strategy, though the filing disclaims this intent.

Risks

• Changes in beneficial ownership can sometimes precede shifts in company strategy or governance, although this filing explicitly denies intent to influence control.
• The concentration of ownership by a single entity could lead to market volatility if their investment strategy changes.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Edgewise Therapeutics. It is a disclosure of beneficial ownership.

Management Comments

• Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake building by investment firms like Paradigm BioCapital is common in the biotechnology sector, often signaling conviction in a company's pipeline or technology, but this filing is purely a disclosure of ownership percentage.

Stakeholder Impact

• Shareholders: May view the increased stake as a positive signal of institutional confidence, but the lack of new company information limits immediate impact.
• Management: May need to engage with Paradigm BioCapital regarding their investment, though the filing disclaims intent to influence control.
• Creditors: No direct impact indicated by this ownership disclosure.

Next Steps

• Monitor future filings from Paradigm BioCapital and Edgewise Therapeutics for any strategic developments or changes in ownership.
• Observe Edgewise Therapeutics' stock performance and operational updates for insights into the impact of this significant ownership.

Key Dates

Keywords

Edgewise Therapeutics, Paradigm BioCapital, Schedule 13G, Beneficial Ownership, Investment Fund, Common Stock, SEC Filing, Shareholder